Case-control study of oral and oropharyngeal cancer in whites and genetic variation in eight metabolic enzymes

Head and Neck

Volumn 30, Issue 9, 2008, Pages 1139-1147

  Buch, Shama C ^a   Nazar Stewart, Valle ^b   Weissfeld, Joel L ^a   Romkes, Marjorie ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Metabolizing enzymes; Oral cancer; Polymorphism; Susceptibility; Tobacco

Indexed keywords

ACYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MYELOPEROXIDASE;

ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENE INTERACTION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; NAT2 GENE; OROPHARYNX CANCER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ARYLAMINE N-ACETYLTRANSFERASE; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2E1; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; ODDS RATIO; OROPHARYNGEAL NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; REFERENCE VALUES; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 51949089097     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20867     Document Type: Article

References (46)

1. Cancer Facts and Figures. American Cancer Society, 2007. Available at http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf (accessed April 9, 2007).
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Walker DM, Boey G, McDonald LA. The pathology of oral cancer. Pathology 2003;35:376-383.
4. Hsu TC, Spitz MR, Schantz SP. Mutagen sensitivity: a biological marker of cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1991;1:83-89.
5. Phillips DH. Fifty years of benzo(a)pyrene. Nature 1983;303:468-472.
6. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4:168-179.
7. Park JY, Muscat JE, Ren Q, et al. CYP1A1 and GSTM1 polymorphisms and oral cancer risk. [erratum appears in Cancer Epidemiol Biomarkers Prev 1997;6:1108]. Cancer Epidemiol Biomarkers Prev 1997;6:791-797.
8. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991;110:559-565.
9. Liu S, Park JY, Schantz SP, Stern JC, Lazarus P. Elucidation of CYP2E1 5′ regulatory RsaI/Pstl allelic variants and their role in risk for oral cancer. Oral Oncol 2001;37:437-445.
10. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet Med 2005;7:463-478.
11. Jourenkova-Mironova N, Mitrunen K, Bouchardy C, Dayer P, Benhamou S, Hirvonen A. High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers. Cancer Res 2000;60:534-536.
12. Parl FF. Glutathione S-transferase genotypes and cancer risk. Cancer Lett 2005;221:123-129.
13. Gronau S, Koenig-Greger D, Jerg M, Riechelmann H. Gene polymorphisms in detoxification enzymes as susceptibility factor for head and neck cancer? Otolaryngol Head Neck Surg 2003;128:674-680.
14. Ko Y, Abel J, Harth V, et al. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 2001;61:4398-4404.
15. Olshan AF, Weissler MC, Watson MA, Bell DA. GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2000;9:185-191.
16. Evans AJ, Henner WD, Eilers KM, et al. Polymorphisms of GSTT1 and related genes in head and neck cancer risk. Head Neck 2004;26:63-70.
17. McWilliams JE, Evans AJ, Beer TM, et al. Genetic polymorphisms in head and neck cancer risk. Head Neck 2000;22:609-617.
18. Lazarus P, Park JY. Metabolizing enzyme genotype and risk for upper aerodigestive tract cancer. Oral Oncol 2000;36:421-431.
19. Pemble S, Schroeder KR, Spencer SR, et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;300:271-276.
20. Hashibe M, Brennan P, Strange RC, et al. Meta-and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1509-1517.
21. Cheng L, Sturgis EM, Eicher SA, Char D, Spitz MR, Wei Q. Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. Int J Cancer 1999;84:220-224.
22. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997;272:10004-10012.
23. Park JY, Schantz SP, Stern JC, Kaur T, Lazarus P. Association between glutathione S-transferase pi genetic polymorphisms and oral cancer risk. [erratum appears in Pharmacogenetics 2000;10:371]. Pharmacogenetics 1999;9:497-504.
24. Katoh T, Kaneko S, Takasawa S, et al. Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer. Pharmacogenetics 1999;9:165-169.
25. Jourenkova-Mironova N, Voho A, Bouchardy C, et al. Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. Int J Cancer 1999;81:44-48.
26. Matthias C, Bockmuhl U, Jahnke V, et al. The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal and laryngeal carcinomas. Pharmacogenetics 1998;8:1-6.
27. Drozdz M, Gierek T, Jendryczko A, Pilch J, Piekarska J. N-acetyltransferase phenotype of patients with cancer of the larynx. Neoplasma 1987;34:481-184.
28. Ho T, Wei Q, Sturgis E. Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. Head Neck 2007;29:682-699. Available at http://dx.doi.org/10.1002/hed.20570 (accessed April 16, 2007).
29. Human NAT2 alleles. Department of Pharmacology and Toxicology, University of Louisville. 2003. Available at http://louisville.edu/medschool/pharmacology/ NAT2.html (accessed December 11, 2006).
30. Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for N-acetyltransferases. [see comment]. Pharmacogenetics 1995;5:1-17.
31. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem 1991;110:407-411.
32. Cascorbi I, Brockmoller J, Roots IA. C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996;56:4965-4969.
33. Kato S, Shields PG, Caporaso NE, et al. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res 1992;52:6712-6715.
34. Harris MJ, Coggan M, Langton L, Wilson SR, Board PG. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics 1998;8:27-31.
35. Benhamou S, Reinikainen M, Bouchardy C, Dayer P, Hirvonen A. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res 1998;58:5291-5293.
36. Bell DA, Thompson CL, Taylor J, et al. Genetic monitoring of human polymorphic cancer susceptibility genes by polymerase chain reaction: application to glutathione transferase mu. Environ Health Perspect 1992;98:113-117.
37. Qin ZS, Niu T, Liu JS. Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 2002;71:1242-1247.
38. Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportion for mutiple alleles. Biometrics 1992;48:361-372.
39. Zhao JH, Curtis D, Sham PC. Model-free analysis and permutation tests for alllic associations. Hum Hered 2000;50:133-139.
40. Sasieni PD. From genotypes to genes: doubling the sample size. Biometrics 1997;53:1253-1261.
41. Breslow NE, Day NE. Statistical methods in cancer research, Vol 1: The analysis of case-control studies. New York: Oxford University Press; 1980.
42. Jourenkova-Mironova N, Wikman H, Bouchardy C, et al. Role of arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2) genotypes in susceptibility to oral/pharyngeal and laryngeal cancers. Pharmacogenetics 1999;9:533-537.
43. Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K, Bell DA. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis 1998;19:1803-1807.
44. Morita S, Yano M, Tsujinaka T, et al. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int J Cancer 1999;80:685-688.
45. Hahn M, Hagedorn G, Kuhlisch E, Schackert HK, Eckelt U. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer. Oral Oncol 2002;38:486-190.
46. Chen C, Ricks S, Doody DR, Fitzgibbons ED, Porter PL, Schwartz SM. N-Acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk. Carcinogenesis 2001;22:1993-1999.